ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model prnasia
August 05, 2021Clinical stage drug development company Pharmaxis Ltd today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) ... -
EffRx Signs Agreement with Pharmaxis for Registration, Commercialization of Bronchitol? americanpharmaceuticalreview
June 14, 2019EffRx Pharmaceuticals has entered into an exclusive license agreement with Pharmaxis, a listed pharmaceutical research company in Australia, for the registration and commercialization of Bronchitol? (mannitol) for cystic fibrosis in Switzerland. -
Pharmaxis Announces Resubmission of Bronchitol NDA
drugs
December 26, 2018Pharmaceutical research company Pharmaxis (ASX: PXS) today announced the resubmission of the Bronchitol New Drug Application with the United States Food and Drug Administration (FDA) by its licensee?? Chiesi Group (Chiesi). -
Pharmaxis Releases Positive Results of for LOXL2 Trial
americanpharmaceuticalreview
October 12, 2018Pharmaxis announced positive results from the Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fib
Pharma Sources Insight January 2025
